#155 – Inside Our Industry – Swift Technology Transfer Could Cut Years off Drug Development Timelines
Posted on | Inside Our Industry
We love manufacturing! But when it can help save or improve lives, it rises to a whole new level! Following are excerpts from a great post on IndustryWeek.com that looks at how the pharmaceutical industry has evolved thanks to COVID-19.
Swift Technology Transfer Could Cut Years off Drug Development Timelines
Nathan Pettus | June 21, 2023 | IndustryWeek.com
The invention, rapid manufacturing and distribution of the COVID-19 vaccine demonstrates exactly how fast the life sciences treatment development pipeline can move when the right factors are in play. Biopharmaceutical treatments commonly take upwards of 15 years to develop, but the COVID vaccine was created and manufactured in only eight months.
A rare, perfect combination of financial investment and emergency authorization paved the path for the vaccine’s rapid development. Life sciences manufacturers have learned many lessons on the value of this acceleration, and it tantalizes the imagination for what could be.
Biopharma organizations are rapidly realizing that, with the right technologies and strategies, they can dramatically accelerate the drug development pipeline, improving and saving lives with new treatments.
Much of that initiative focuses on a critical strategy: shortening and streamlining technology transfer, where life sciences process specifications are transferred from early development stages to commercial production.
Today the process is largely manual. Yet the right technology, open standards and operational buy-in have the potential to reduce the technology transfer process to a fraction of the time it takes today. Stakeholders from manufacturers to automation suppliers are already putting resources into a research center and grassroots consortium to make that vision—known in the industry as one-click technology transfer (OCTT)—a reality.
After seeing the fast development and delivery of the COVID vaccine, life sciences manufacturers are optimistic about shortening the technology transfer process, and many of the pieces to accomplish this are already in place. Life sciences companies have very mature automation systems installed at their facilities, ready to receive information and run new treatments through the manufacturing process. They also have mature enterprise resource planning (ERP) systems in place, helping them procure supplies, know where product will ship and know what sites to use for the most efficient production. Today, most companies can easily identify which sites have the capacity they need to execute at the scale they desire.
Where these companies tend to be weak in technology transfer is in digitalizing the treatment recipe from drug discovery and development all the way across the pipeline until it is manufactured at scale. This is the most important stage of the technology transfer process—if critical information is stuck in paper notebooks, the computerized systems designed to increase speed to market cannot use it.
Fortunately, companies are developing the framework for a centralized transport and translation platform. New tools—for example, process and knowledge management software—are closing the gap to speed technology transfer. These holistic software packages electronically capture every decision made in the treatment development process. Not only is information more standardized and reliable, but process parameters and calculations are automatically managed, facilitating easier scale-up in every stage of development.
The world has seen what is possible with expedited treatment manufacturing. Such a change would dramatically improve the lives of patients around the world, especially considering the many new treatment technologies emerging in the marketplace. The tools and technologies to accomplish a step change in the life sciences exist. Now, the key players simply need to get in the game.
Nathan Pettus was named president of Emerson’s Process Systems and Solutions business in June 2021. He oversees a business that helps some of the world’s leading companies in a wide variety of industries leverage automation software and technologies to optimize operations, protect personnel and reach sustainability targets.